1 Market Overview

• 1.1 Product Overview and Scope
• 1.2 Market Estimation Caveats and Base Year
• 1.3 Classification of Personalized Medicine for Cancer by Type
  • 1.3.1 Overview: Global Personalized Medicine for Cancer Market Size by Type: 2020 Versus 2024 Versus 2031
  • 1.3.2 Global Personalized Medicine for Cancer Consumption Value Market Share by Type in 2024
  • 1.3.3 Immunotherapy
  • 1.3.4 Targeted Therapy
  • 1.3.5 Chemotherapy
  • 1.3.6 Hormone Therapy
  • 1.3.7 Others
• 1.4 Global Personalized Medicine for Cancer Market by Application
  • 1.4.1 Overview: Global Personalized Medicine for Cancer Market Size by Application: 2020 Versus 2024 Versus 2031
  • 1.4.2 Breast Cancer
  • 1.4.3 Blood Cancer
  • 1.4.4 Gastrointestinal Cancer
  • 1.4.5 Prostate Cancer
  • 1.4.6 Skin Cancer
  • 1.4.7 Lung Cancer
  • 1.4.8 Others
• 1.5 Global Personalized Medicine for Cancer Market Size & Forecast
• 1.6 Global Personalized Medicine for Cancer Market Size and Forecast by Region
  • 1.6.1 Global Personalized Medicine for Cancer Market Size by Region: 2020 VS 2024 VS 2031
  • 1.6.2 Global Personalized Medicine for Cancer Market Size by Region, (2020-2031)
  • 1.6.3 North America Personalized Medicine for Cancer Market Size and Prospect (2020-2031)
  • 1.6.4 Europe Personalized Medicine for Cancer Market Size and Prospect (2020-2031)
  • 1.6.5 Asia-Pacific Personalized Medicine for Cancer Market Size and Prospect (2020-2031)
  • 1.6.6 South America Personalized Medicine for Cancer Market Size and Prospect (2020-2031)
  • 1.6.7 Middle East & Africa Personalized Medicine for Cancer Market Size and Prospect (2020-2031)

2 Company Profiles

• 2.1 Bayer
  • 2.1.1 Bayer Details
  • 2.1.2 Bayer Major Business
  • 2.1.3 Bayer Personalized Medicine for Cancer Product and Solutions
  • 2.1.4 Bayer Personalized Medicine for Cancer Revenue, Gross Margin and Market Share (2020-2025)
  • 2.1.5 Bayer Recent Developments and Future Plans
• 2.2 GlaxoSmithKline
  • 2.2.1 GlaxoSmithKline Details
  • 2.2.2 GlaxoSmithKline Major Business
  • 2.2.3 GlaxoSmithKline Personalized Medicine for Cancer Product and Solutions
  • 2.2.4 GlaxoSmithKline Personalized Medicine for Cancer Revenue, Gross Margin and Market Share (2020-2025)
  • 2.2.5 GlaxoSmithKline Recent Developments and Future Plans
• 2.3 Novartis
  • 2.3.1 Novartis Details
  • 2.3.2 Novartis Major Business
  • 2.3.3 Novartis Personalized Medicine for Cancer Product and Solutions
  • 2.3.4 Novartis Personalized Medicine for Cancer Revenue, Gross Margin and Market Share (2020-2025)
  • 2.3.5 Novartis Recent Developments and Future Plans
• 2.4 Sanofi
  • 2.4.1 Sanofi Details
  • 2.4.2 Sanofi Major Business
  • 2.4.3 Sanofi Personalized Medicine for Cancer Product and Solutions
  • 2.4.4 Sanofi Personalized Medicine for Cancer Revenue, Gross Margin and Market Share (2020-2025)
  • 2.4.5 Sanofi Recent Developments and Future Plans
• 2.5 Pfizer
  • 2.5.1 Pfizer Details
  • 2.5.2 Pfizer Major Business
  • 2.5.3 Pfizer Personalized Medicine for Cancer Product and Solutions
  • 2.5.4 Pfizer Personalized Medicine for Cancer Revenue, Gross Margin and Market Share (2020-2025)
  • 2.5.5 Pfizer Recent Developments and Future Plans
• 2.6 Amgen
  • 2.6.1 Amgen Details
  • 2.6.2 Amgen Major Business
  • 2.6.3 Amgen Personalized Medicine for Cancer Product and Solutions
  • 2.6.4 Amgen Personalized Medicine for Cancer Revenue, Gross Margin and Market Share (2020-2025)
  • 2.6.5 Amgen Recent Developments and Future Plans
• 2.7 Merck
  • 2.7.1 Merck Details
  • 2.7.2 Merck Major Business
  • 2.7.3 Merck Personalized Medicine for Cancer Product and Solutions
  • 2.7.4 Merck Personalized Medicine for Cancer Revenue, Gross Margin and Market Share (2020-2025)
  • 2.7.5 Merck Recent Developments and Future Plans
• 2.8 Bristol-Myers Squibb
  • 2.8.1 Bristol-Myers Squibb Details
  • 2.8.2 Bristol-Myers Squibb Major Business
  • 2.8.3 Bristol-Myers Squibb Personalized Medicine for Cancer Product and Solutions
  • 2.8.4 Bristol-Myers Squibb Personalized Medicine for Cancer Revenue, Gross Margin and Market Share (2020-2025)
  • 2.8.5 Bristol-Myers Squibb Recent Developments and Future Plans
• 2.9 Ariad Pharmaceuticals (Takeda)
  • 2.9.1 Ariad Pharmaceuticals (Takeda) Details
  • 2.9.2 Ariad Pharmaceuticals (Takeda) Major Business
  • 2.9.3 Ariad Pharmaceuticals (Takeda) Personalized Medicine for Cancer Product and Solutions
  • 2.9.4 Ariad Pharmaceuticals (Takeda) Personalized Medicine for Cancer Revenue, Gross Margin and Market Share (2020-2025)
  • 2.9.5 Ariad Pharmaceuticals (Takeda) Recent Developments and Future Plans
• 2.10 Eli Lilly
  • 2.10.1 Eli Lilly Details
  • 2.10.2 Eli Lilly Major Business
  • 2.10.3 Eli Lilly Personalized Medicine for Cancer Product and Solutions
  • 2.10.4 Eli Lilly Personalized Medicine for Cancer Revenue, Gross Margin and Market Share (2020-2025)
  • 2.10.5 Eli Lilly Recent Developments and Future Plans
• 2.11 Roche
  • 2.11.1 Roche Details
  • 2.11.2 Roche Major Business
  • 2.11.3 Roche Personalized Medicine for Cancer Product and Solutions
  • 2.11.4 Roche Personalized Medicine for Cancer Revenue, Gross Margin and Market Share (2020-2025)
  • 2.11.5 Roche Recent Developments and Future Plans
• 2.12 Boehringer Ingelheim
  • 2.12.1 Boehringer Ingelheim Details
  • 2.12.2 Boehringer Ingelheim Major Business
  • 2.12.3 Boehringer Ingelheim Personalized Medicine for Cancer Product and Solutions
  • 2.12.4 Boehringer Ingelheim Personalized Medicine for Cancer Revenue, Gross Margin and Market Share (2020-2025)
  • 2.12.5 Boehringer Ingelheim Recent Developments and Future Plans
• 2.13 Johnson and Johnson
  • 2.13.1 Johnson and Johnson Details
  • 2.13.2 Johnson and Johnson Major Business
  • 2.13.3 Johnson and Johnson Personalized Medicine for Cancer Product and Solutions
  • 2.13.4 Johnson and Johnson Personalized Medicine for Cancer Revenue, Gross Margin and Market Share (2020-2025)
  • 2.13.5 Johnson and Johnson Recent Developments and Future Plans
• 2.14 Teva Pharmaceuticals
  • 2.14.1 Teva Pharmaceuticals Details
  • 2.14.2 Teva Pharmaceuticals Major Business
  • 2.14.3 Teva Pharmaceuticals Personalized Medicine for Cancer Product and Solutions
  • 2.14.4 Teva Pharmaceuticals Personalized Medicine for Cancer Revenue, Gross Margin and Market Share (2020-2025)
  • 2.14.5 Teva Pharmaceuticals Recent Developments and Future Plans

3 Market Competition, by Players

• 3.1 Global Personalized Medicine for Cancer Revenue and Share by Players (2020-2025)
• 3.2 Market Share Analysis (2024)
  • 3.2.1 Market Share of Personalized Medicine for Cancer by Company Revenue
  • 3.2.2 Top 3 Personalized Medicine for Cancer Players Market Share in 2024
  • 3.2.3 Top 6 Personalized Medicine for Cancer Players Market Share in 2024
• 3.3 Personalized Medicine for Cancer Market: Overall Company Footprint Analysis
  • 3.3.1 Personalized Medicine for Cancer Market: Region Footprint
  • 3.3.2 Personalized Medicine for Cancer Market: Company Product Type Footprint
  • 3.3.3 Personalized Medicine for Cancer Market: Company Product Application Footprint
• 3.4 New Market Entrants and Barriers to Market Entry
• 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

• 4.1 Global Personalized Medicine for Cancer Consumption Value and Market Share by Type (2020-2025)
• 4.2 Global Personalized Medicine for Cancer Market Forecast by Type (2026-2031)

5 Market Size Segment by Application

• 5.1 Global Personalized Medicine for Cancer Consumption Value Market Share by Application (2020-2025)
• 5.2 Global Personalized Medicine for Cancer Market Forecast by Application (2026-2031)

6 North America

• 6.1 North America Personalized Medicine for Cancer Consumption Value by Type (2020-2031)
• 6.2 North America Personalized Medicine for Cancer Market Size by Application (2020-2031)
• 6.3 North America Personalized Medicine for Cancer Market Size by Country
  • 6.3.1 North America Personalized Medicine for Cancer Consumption Value by Country (2020-2031)
  • 6.3.2 United States Personalized Medicine for Cancer Market Size and Forecast (2020-2031)
  • 6.3.3 Canada Personalized Medicine for Cancer Market Size and Forecast (2020-2031)
  • 6.3.4 Mexico Personalized Medicine for Cancer Market Size and Forecast (2020-2031)

7 Europe

• 7.1 Europe Personalized Medicine for Cancer Consumption Value by Type (2020-2031)
• 7.2 Europe Personalized Medicine for Cancer Consumption Value by Application (2020-2031)
• 7.3 Europe Personalized Medicine for Cancer Market Size by Country
  • 7.3.1 Europe Personalized Medicine for Cancer Consumption Value by Country (2020-2031)
  • 7.3.2 Germany Personalized Medicine for Cancer Market Size and Forecast (2020-2031)
  • 7.3.3 France Personalized Medicine for Cancer Market Size and Forecast (2020-2031)
  • 7.3.4 United Kingdom Personalized Medicine for Cancer Market Size and Forecast (2020-2031)
  • 7.3.5 Russia Personalized Medicine for Cancer Market Size and Forecast (2020-2031)
  • 7.3.6 Italy Personalized Medicine for Cancer Market Size and Forecast (2020-2031)

8 Asia-Pacific

• 8.1 Asia-Pacific Personalized Medicine for Cancer Consumption Value by Type (2020-2031)
• 8.2 Asia-Pacific Personalized Medicine for Cancer Consumption Value by Application (2020-2031)
• 8.3 Asia-Pacific Personalized Medicine for Cancer Market Size by Region
  • 8.3.1 Asia-Pacific Personalized Medicine for Cancer Consumption Value by Region (2020-2031)
  • 8.3.2 China Personalized Medicine for Cancer Market Size and Forecast (2020-2031)
  • 8.3.3 Japan Personalized Medicine for Cancer Market Size and Forecast (2020-2031)
  • 8.3.4 South Korea Personalized Medicine for Cancer Market Size and Forecast (2020-2031)
  • 8.3.5 India Personalized Medicine for Cancer Market Size and Forecast (2020-2031)
  • 8.3.6 Southeast Asia Personalized Medicine for Cancer Market Size and Forecast (2020-2031)
  • 8.3.7 Australia Personalized Medicine for Cancer Market Size and Forecast (2020-2031)

9 South America

• 9.1 South America Personalized Medicine for Cancer Consumption Value by Type (2020-2031)
• 9.2 South America Personalized Medicine for Cancer Consumption Value by Application (2020-2031)
• 9.3 South America Personalized Medicine for Cancer Market Size by Country
  • 9.3.1 South America Personalized Medicine for Cancer Consumption Value by Country (2020-2031)
  • 9.3.2 Brazil Personalized Medicine for Cancer Market Size and Forecast (2020-2031)
  • 9.3.3 Argentina Personalized Medicine for Cancer Market Size and Forecast (2020-2031)

10 Middle East & Africa

• 10.1 Middle East & Africa Personalized Medicine for Cancer Consumption Value by Type (2020-2031)
• 10.2 Middle East & Africa Personalized Medicine for Cancer Consumption Value by Application (2020-2031)
• 10.3 Middle East & Africa Personalized Medicine for Cancer Market Size by Country
  • 10.3.1 Middle East & Africa Personalized Medicine for Cancer Consumption Value by Country (2020-2031)
  • 10.3.2 Turkey Personalized Medicine for Cancer Market Size and Forecast (2020-2031)
  • 10.3.3 Saudi Arabia Personalized Medicine for Cancer Market Size and Forecast (2020-2031)
  • 10.3.4 UAE Personalized Medicine for Cancer Market Size and Forecast (2020-2031)

11 Market Dynamics

• 11.1 Personalized Medicine for Cancer Market Drivers
• 11.2 Personalized Medicine for Cancer Market Restraints
• 11.3 Personalized Medicine for Cancer Trends Analysis
• 11.4 Porters Five Forces Analysis
  • 11.4.1 Threat of New Entrants
  • 11.4.2 Bargaining Power of Suppliers
  • 11.4.3 Bargaining Power of Buyers
  • 11.4.4 Threat of Substitutes
  • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

• 12.1 Personalized Medicine for Cancer Industry Chain
• 12.2 Personalized Medicine for Cancer Upstream Analysis
• 12.3 Personalized Medicine for Cancer Midstream Analysis
• 12.4 Personalized Medicine for Cancer Downstream Analysis

13 Research Findings and Conclusion

14 Appendix

• 14.1 Methodology
• 14.2 Research Process and Data Source

According to our (Global Info Research) latest study, the global Personalized Medicine for Cancer market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report is a detailed and comprehensive analysis for global Personalized Medicine for Cancer market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Personalized Medicine for Cancer market size and forecasts, in consumption value ($ Million), 2020-2031
Global Personalized Medicine for Cancer market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Personalized Medicine for Cancer market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Personalized Medicine for Cancer market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Personalized Medicine for Cancer
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Personalized Medicine for Cancer market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bayer, GlaxoSmithKline, Novartis, Sanofi, Pfizer, Amgen, Merck, Bristol-Myers Squibb, Ariad Pharmaceuticals (Takeda), Eli Lilly, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Personalized Medicine for Cancer market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Immunotherapy
Targeted Therapy
Chemotherapy
Hormone Therapy
Others
Market segment by Application
Breast Cancer
Blood Cancer
Gastrointestinal Cancer
Prostate Cancer
Skin Cancer
Lung Cancer
Others
Market segment by players, this report covers
Bayer
GlaxoSmithKline
Novartis
Sanofi
Pfizer
Amgen
Merck
Bristol-Myers Squibb
Ariad Pharmaceuticals (Takeda)
Eli Lilly
Roche
Boehringer Ingelheim
Johnson and Johnson
Teva Pharmaceuticals
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Personalized Medicine for Cancer product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Personalized Medicine for Cancer, with revenue, gross margin, and global market share of Personalized Medicine for Cancer from 2020 to 2025.
Chapter 3, the Personalized Medicine for Cancer competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Personalized Medicine for Cancer market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Personalized Medicine for Cancer.
Chapter 13, to describe Personalized Medicine for Cancer research findings and conclusion.